More HIV funding cuts are coming for SA. This time it’s a slow fade, but with clear risks

Experts say South Africa’s contradictory approach to drugs — treating addiction as both a disease and a crime — is fuelling a worsening crisis in places like Westbury, where illicit drugs plague the community

SA’s first consignment of the twice-a-year anti-HIV injection, lenacapavir — 37 920 doses — arrived last week at OR Tambo Airport via two shipments from Dublin. The batches reached the country six weeks later than expected. The delay of the shipment meant the health department couldn’t start its roll-out on April 1, as it had originally planned, and had to postpone it to mid to late May

As wars disrupt fuel supplies and health systems, more women are being forced to give birth without timely access to skilled care

Health Minister Aaron Motsoaledi has met the South African Medical Association — one of the organisations taking him to court about the National Health Insurance Act — to talk about “things we have in common”. President Cyril Ramaphosa is planning to meet Business Unity South Africa again after an initial meeting in 2024, during which they discussed alternatives to the NHI

Norbert Ndjeka was born on World TB Day. Decades later, he would reshape how South Africa treats the deadliest forms of the disease

The HIV prevention shot, lenacapavir, will be rolled out at South African clinics within the next couple of months and from 2027, the health department will also buy generics. But how best to spend the HIV prevention budget so that the country can drive infections down as fast as possible? We take a look at what the modelling data shows

Six years after Cyclone Idai ripped through Beira, the city’s wounds — physical and psychological — are still raw. As a new storm gathered in the Indian Ocean in February, journalist Sean Christie found a city caught in a permanent state of waiting for the next disaster to hit.

South Africa’s National Aids Council, Sanac, has asked local drug companies to submit applications by April 7 to make generic versions of an anti-HIV jab that could end Aids by 2043 in the country. The original version of the once-every-six-months shot, known as lenacapavir, is produced by the US pharmaceutical company, Gilead Sciences. Sanac will submit a shortlist of successful applicants, who met the requirements of the Council’s expression of interest call, to Gilead by July.

Together with sanitary pad and pantyliner manufacturers, specialists say there is no evidence of a health risk even though a UFS study has found they contain hormone-disrupting chemicals

As the Earth becomes hotter, we’re seeing more floods and droughts. Flooding can make superbugs spread faster and further. And heat helps germs adapt faster

Manufacturers and industry groups argue that endocrine-disrupting chemicals in menstrual products are present at extremely low levels and do not compromise safety

A pending court complaint alleges bias after the regulator voted to block radio advertisements about the dangers of sugar